Skip to main content
Clinical Trials/JPRN-UMIN000040948
JPRN-UMIN000040948
Recruiting
未知

A prospective study of the efficacy and safety of preoperative chemotherapy with gemcitabine+nab-paclitaxel therapy for resectable pancreatic body and tail cancer with splenic arteriovenous invasion by image. - A prospective study of the efficacy and safety of preoperative chemotherapy for resectable pancreatic body and tail cancer with splenic arteriovenous invasion by image.

Wakayama medical university0 sites49 target enrollmentJuly 1, 2020

Overview

Phase
未知
Intervention
Not specified
Conditions
pancreatic cancer
Sponsor
Wakayama medical university
Enrollment
49
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 1, 2020
End Date
March 31, 2025
Last Updated
2 years ago
Study Type
Others,meta-analysis etc
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\. Cases with a history of severe drug hypersensitivity or drug allergy 2\. Cases with a history of malignant tumor 3\. Cases with active infection 4\. Patients with peripheral sensory neuropathy (Grade 2 or higher) 5\. Cases with a history of interstitial pneumonia or pulmonary fibrosis 6\. Patients with uncontrolled ascites or pleural effusion 7\. Cases with uncontrolled diabetes 8\. Cases with Uncontrolled congestive heart failure, angina, hypertension, arrhythmia 9\. Cases with history of neurologically or psychologically significant disease 10\. Cases with diarrhea 11\. Pregnant women, lactating women, and women who may be pregnant (will), or women and men who are not willing to contracept during the study period and for a certain period (180 days) after the last administration of study drug 12\. Other cases that the doctor has determined to be unsuitable for participation in this clinical trial 13\. Cases which conforms to Borderline Resectable/Unresectable of NCCN guidelines (Version 1\.2020\) by MDCT diagnosis. 14\. Patients with active hepatitis B

Outcomes

Primary Outcomes

Not specified

Similar Trials